Citius Pharmaceuticals Inc
Company Profile
Business description
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.
Contact
11 Commerce Drive
First Floor
CranfordNJ07016
USAT: +1 908 967-6677
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2025
Employees
23
Stocks News & Analysis
stocks
Ask the analyst: Can this big Covid loser scale its former heights?
stocks
The fight for Insignia continues
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,660.40 | 31.30 | 0.36% |
| CAC 40 | 7,888.30 | 39.32 | -0.50% |
| DAX 40 | 21,228.04 | 166.89 | -0.78% |
| Dow JONES (US) | 44,424.25 | 140.82 | -0.32% |
| FTSE 100 | 8,486.31 | 16.04 | -0.19% |
| HKSE | 20,197.77 | 131.58 | 0.66% |
| NASDAQ | 19,954.30 | 99.38 | -0.50% |
| Nikkei 225 | 39,565.80 | 366.18 | -0.92% |
| NZX 50 Index | 12,999.72 | 24.98 | -0.19% |
| S&P 500 | 6,101.24 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,408.90 | 30.20 | 0.36% |
| SSE Composite Index | 3,250.60 | 2.03 | -0.06% |